2xhd
From Proteopedia
(Difference between revisions)
| (10 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | {{Seed}} | ||
| - | [[Image:2xhd.jpg|left|200px]] | ||
| - | + | ==Crystal structure of N-((2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H- inden-2-yl)-2-propanesulfonamide in complex with the ligand binding domain of the human GluA2 receptor== | |
| - | + | <StructureSection load='2xhd' size='340' side='right'caption='[[2xhd]], [[Resolution|resolution]] 1.80Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[2xhd]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2XHD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2XHD FirstGlance]. <br> | |
| - | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.8Å</td></tr> | |
| - | --> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=7T9:N-[(2S)-5-(6-FLUORO-3-PYRIDINYL)-2,3-DIHYDRO-1H-INDEN-2-YL]-2-PROPANESULFONAMIDE'>7T9</scene>, <scene name='pdbligand=GLU:GLUTAMIC+ACID'>GLU</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> |
| - | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2xhd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2xhd OCA], [https://pdbe.org/2xhd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2xhd RCSB], [https://www.ebi.ac.uk/pdbsum/2xhd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2xhd ProSAT]</span></td></tr> | |
| + | </table> | ||
| + | == Evolutionary Conservation == | ||
| + | [[Image:Consurf_key_small.gif|200px|right]] | ||
| + | Check<jmol> | ||
| + | <jmolCheckbox> | ||
| + | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/xh/2xhd_consurf.spt"</scriptWhenChecked> | ||
| + | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview03.spt</scriptWhenUnchecked> | ||
| + | <text>to colour the structure by Evolutionary Conservation</text> | ||
| + | </jmolCheckbox> | ||
| + | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=2xhd ConSurf]. | ||
| + | <div style="clear:both"></div> | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | A series of AMPA receptor positive allosteric modulators has been optimized from poorly penetrant leads to identify molecules with excellent preclinical pharmacokinetics and CNS penetration. These discoveries led to 17i, a potent, efficacious CNS penetrant molecule with an excellent pharmacokinetic profile across preclinical species, which is well tolerated and is also orally bioavailable in humans. | ||
| - | + | Discovery of N-[(2S)-5-(6-Fluoro-3-pyridinyl)-2,3-dihydro-1H-inden-2-yl]-2-propanesulfo namide, a Novel Clinical AMPA Receptor Positive Modulator.,Ward SE, Harries M, Aldegheri L, Andreotti D, Ballantine S, Bax BD, Harris AJ, Harker AJ, Lund J, Melarange R, Mingardi A, Mookherjee C, Mosley J, Neve M, Oliosi B, Profeta R, Smith KJ, Smith PW, Spada S, Thewlis KM, Yusaf SP J Med Chem. 2010 Jul 8. PMID:20614889<ref>PMID:20614889</ref> | |
| + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| + | </div> | ||
| + | <div class="pdbe-citations 2xhd" style="background-color:#fffaf0;"></div> | ||
| - | + | ==See Also== | |
| - | + | *[[Glutamate receptor 3D structures|Glutamate receptor 3D structures]] | |
| - | + | == References == | |
| - | + | <references/> | |
| - | + | __TOC__ | |
| - | + | </StructureSection> | |
| - | == | + | |
| - | + | ||
| - | + | ||
| - | == | + | |
| - | < | + | |
[[Category: Homo sapiens]] | [[Category: Homo sapiens]] | ||
| - | [[Category: Aldegheri | + | [[Category: Large Structures]] |
| - | [[Category: Andreotti | + | [[Category: Aldegheri L]] |
| - | [[Category: Ballantine | + | [[Category: Andreotti D]] |
| - | [[Category: Bax | + | [[Category: Ballantine S]] |
| - | [[Category: Harker | + | [[Category: Bax BD]] |
| - | [[Category: Harries | + | [[Category: Harker AJ]] |
| - | [[Category: Harris | + | [[Category: Harries M]] |
| - | [[Category: Lund | + | [[Category: Harris AJ]] |
| - | [[Category: Melarange | + | [[Category: Lund J]] |
| - | [[Category: Mingardi | + | [[Category: Melarange R]] |
| - | [[Category: Mookherjee | + | [[Category: Mingardi A]] |
| - | [[Category: Mosley | + | [[Category: Mookherjee C]] |
| - | [[Category: Neve | + | [[Category: Mosley J]] |
| - | [[Category: Oliosi | + | [[Category: Neve M]] |
| - | [[Category: Profeta | + | [[Category: Oliosi B]] |
| - | [[Category: Smith | + | [[Category: Profeta R]] |
| - | [[Category: Smith | + | [[Category: Smith KJ]] |
| - | [[Category: Spada | + | [[Category: Smith PW]] |
| - | [[Category: Thewlis | + | [[Category: Spada S]] |
| - | [[Category: Ward | + | [[Category: Thewlis KM]] |
| - | [[Category: Yusaf | + | [[Category: Ward SE]] |
| - | + | [[Category: Yusaf SP]] | |
| - | + | ||
| - | + | ||
| - | + | ||
Current revision
Crystal structure of N-((2S)-5-(6-fluoro-3-pyridinyl)-2,3-dihydro-1H- inden-2-yl)-2-propanesulfonamide in complex with the ligand binding domain of the human GluA2 receptor
| |||||||||||
Categories: Homo sapiens | Large Structures | Aldegheri L | Andreotti D | Ballantine S | Bax BD | Harker AJ | Harries M | Harris AJ | Lund J | Melarange R | Mingardi A | Mookherjee C | Mosley J | Neve M | Oliosi B | Profeta R | Smith KJ | Smith PW | Spada S | Thewlis KM | Ward SE | Yusaf SP

